Why the study?
This review was conducted to examine proposed diagnostic criteria, prevalence, prognostic value, and predictors of reverse and adverse cardiac remodelling in heart failure, focusing primarily on heart failure with reduced ejection fraction.
This expert review outlines the diagnostic criteria, prognostic value, and predictors of cardiac remodelling in heart failure patients.
Answers are grounded in this paper and cite their sources.
May aid standardized assessment of remodelling in HF; leaves open prospective validation for therapeutic guidance.
In patients with heart failure, the beneficial effects of drug and device therapies counteract to some extent ongoing cardiac damage. According to the net balance between these two factors, cardiac geometry and function may improve (reverse remodelling, RR) and even completely normalize (remission), or vice versa progressively deteriorate (adverse remodelling, AR). RR or remission predict a better prognosis, while AR has been associated with worsening clinical status and outcomes. The remodelling process ultimately involves all cardiac chambers, but has been traditionally evaluated in terms of left ventricular volumes and ejection fraction. This is the second part of a review paper by the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology dedicated to ventricular remodelling. This document examines the proposed criteria to diagnose RR and AR, their prevalence and prognostic value, and the variables predicting remodelling in patients managed according to current guidelines. Much attention will be devoted to RR in patients with heart failure with reduced ejection fraction because most studies on cardiac remodelling focused on this setting.
No takes yet. Share an insight, caveat, or question.
Aimo et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: